Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

NCT07297979 | Recruiting Phase 1 FDA Drug

• 1 other identifier: 20200034
• Study Type: interventional
• Target: 50
• Locations: 2 countries
• Sites: 3

Brief Summary

The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

Conditions

Ewing Sarcoma

Keywords

Relapsed or refractory Ewing sarcoma; EWS; Xaluritamig; AMG 509

Outcome Measures

Primary Outcomes (2)

• Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)

  Up to 42 days

• Number of Participants with Treatment-emergent Adverse Events

  This includes treatment-emergent, treatment-related, serious, and fatal adverse events. Any changes in safety assessments (vital signs and clinical laboratory tests) will be recorded as adverse events.

  Up to approximately 2.5 years

Secondary Outcomes (16)

• Maximum Serum Concentration (Cmax) of Xaluritamig

  Up to approximately 6 months

• Time to Cmax (tmax) of Xaluritamig

  Up to approximately 6 months

• Minimum Serum Concentration (Cmin) of Xaluritamig

  Up to approximately 6 months

• Accumulation Following Multiple Doses of Xaluritamig

  Up to approximately 6 months

• Serum Concentration Before Dosing (Ctrough) of Xaluritamig

  Up to approximately 6 months

Study Arms (2)

Part 1 (Dose Confirmation)

EXPERIMENTAL

Part 1 will begin with a pre-specified xaluritamig target dose and frequency. Multiple dose levels and/or alternative dose regimens may be explored in parallel to determine 1 or more recommended doses for expansion, which is/are considered safe, based on emerging data.

Drug: Xaluritamig

Part 2 (Dose Expansion)

EXPERIMENTAL

Participants will be treated in Part 2 after the recommended doses for expansion for xaluritamig are determined in Part 1 to further characterize preliminary antitumor activity and safety.

Drug: Xaluritamig

Interventions

Xaluritamig DRUG

Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Also known as: AMG 509

Part 1 (Dose Confirmation); Part 2 (Dose Expansion)

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Part 1: evaluable disease as defined by RECIST v1.1, as determined by the site investigator.
• Part 2: measurable disease as defined by RECIST v1.1, as determined by the site investigator.
• Histologically or cytologically confirmed EWS with molecular evidence of an EWSR1 translocation with an E26 transformation-specific (ETS) family gene, eg, FLI1, ETS-related gene \[ERG\]) via next generation sequencing (based on local testing).
• Relapsed or refractory EWS following at least 1 line of chemotherapy (including treatment with an anthracycline and at least 1 alkylating agent).
• Performance status:
• Karnofsky ≥ 70% for participants ≥ 16 years of age.
• Lansky ≥ 70% for participants \< 16 years of age.
• Adequate organ function, defined as follows:
• a. Hematological function: i. Absolute neutrophil count ≥ 1.0 x 109/L, provided that:
• the participant has not received short-acting growth factor support within 7 days before screening assessment, and
• the participant has not received long-acting growth factor support within 14 days before screening assessment.
• ii. Platelet count ≥ 75 x 109/L, provided that:
• the participant has not received a platelet transfusion within 7 days before screening assessment, and
• the participant has not received a platelet stimulating agent within 14 days before screening assessment.
• b. Renal function: i. Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation ≥ 30 mL/min/1.73 m\^2 for participants ≥ 18 years of age.

You may not qualify if:

• Untreated central nervous system (CNS) metastases or leptomeningeal disease. Participants with a history of treated CNS metastases are eligible if there is radiographic evidence of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study.
• History of other malignancy within the past 2 years, except for malignancy treated with curative intent with low risk for recurrence (approximately \< 10%) and with no known active disease present for \>1 year before enrollment.
• Active autoimmune disease that has required systemic treatment (except physiologic adrenal hormone replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. Participants with Type 1 diabetes, vitiligo, psoriasis, hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are permitted.
• Participants who received anti-cancer therapy administered within the following minimum washout periods prior to first dose of xaluritamig:
• Cytotoxic chemotherapy: 21 days.
• Small molecules including tyrosine kinase inhibitors: 7 days or 5 half-lives, whichever is shorter.
• Monoclonal antibodies, immune checkpoint inhibitors, bispecific antibodies and other biologic agents: 28 days or 5 half-lives, whichever is shorter.
• Cellular therapies including Chimeric Antigen Receptor T-cell therapy (CAR-T), adoptive T-cell therapy: 56 days.
• Radiotherapy: 14 days for focal therapy, 28 days for large field therapy or involving \> 30% of the bone marrow.
• Stem cell transplant: 12 weeks for autologous, 6 months for allogeneic, with no active graft-versus-host disease.
• Any other therapy or investigational agent: 28 days or 5 half-lives, whichever is longer.
• Requirement for chronic systemic corticosteroid therapy (prednisone dose \> 10 mg/day \[\> 0.25 mg/kg/day if \< 40 kg\] or equivalent) or any other immunosuppressive therapies (including anti-tumour necrosis factor α (TNFα) therapies) unless stopped (with adequate tapering) within 28 days before first dose of xaluritamig.
• Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant, donate eggs, or breastfeed while on trial until an additional 6 months after the last dose of trial intervention.
• Unwilling to abstain from donating sperm during treatment and for an additional 6 months after the last dose of xaluritamig.

Sponsors & Collaborators

• Amgen: lead

Study Sites (3)

University of California Los Angeles

Los Angeles, California, 90995-1752, United States

RECRUITING

Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia

RECRUITING

Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia

RECRUITING

Related Links

• AmgenTrials clinical trials website

MeSH Terms

Conditions

Sarcoma, Ewing; Recurrence

Condition Hierarchy (Ancestors)

Osteosarcoma; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• MD

  Amgen

  STUDY DIRECTOR

Central Study Contacts

Amgen Call Center

CONTACT

866-572-6436; medinfo@amgen.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2025
• First Posted: December 22, 2025
• Study Start: April 8, 2026
• Primary Completion (Estimated): May 26, 2030
• Study Completion (Estimated): May 26, 2030
• Last Updated: April 16, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Locations

AU (2); US (1)